Evidence map›Paper›PMID 33852100›Full record

ArticleAnnals of surgical oncology2021

Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group.

Carol J Swallow, Dirk C Strauss, Sylvie Bonvalot, Piotr Rutkowski, Anant Desai, Rebecca A Gladdy, Ricardo Gonzalez, David E Gyorki, Mark Fairweather, Winan J van Houdt and 24 more

Open access · greenAbstract readConsensus Statement
In one paragraph

Article in Annals of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 7 pooled it
23.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 7 syntheses or guidelines pooled it, 231 citations in OpenAlex.

  1. Guideline
  2. SEOM-GEIS Spanish clinical guidelines for the management of soft‑tissue sarcomas (2024).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Guideline
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors at 20 institutions in 10 countries.

Carol J SwallowDepartment of Surgical Oncology, Princess Margaret Cancer Centre/Mount Sinai Hospital, Toronto, ON, Canada. Carol.Swallow@sinaihealth.ca.
Dirk C StraussSarcoma Unit, Department of Academic Surgery, Royal Marsden Hospital, Royal Marsden NHS Foundation Trust, London, UK. dirk.strauss@rmh.nhs.uk.
Sylvie BonvalotDepartment of Surgical Oncology, Institut Curie, PSL University, Paris, France.
Piotr RutkowskiDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Anant DesaiDepartment of Surgery, University Hospitals Birmingham, Birmingham, UK.
Rebecca A GladdyDepartment of Surgical Oncology, Princess Margaret Cancer Centre/Mount Sinai Hospital, Toronto, ON, Canada.
Ricardo GonzalezSarcoma Department, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
David E GyorkiDepartment of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Mark FairweatherDepartment of Surgery, Brigham and Women's Hospital, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Winan J van HoudtDepartment of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Eberhard StoeckleDepartment of Surgery, Institut Bergonie, Bordeaux, France.
Jae Berm ParkDepartment of Surgery, Samsung Medical Center, Seoul, South Korea.
Markus AlbertsmeierDepartment of General, Visceral and Transplantation Surgery, Ludwig-Maximilians-Universität, University Hospital, Munich, Germany.
Carolyn NessimDepartment of Surgery, University of Ottawa, Ottawa, ON, Canada.
Kenneth CardonaDepartment of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Marco FioreDepartment of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Andrew HayesSarcoma Unit, Department of Academic Surgery, Royal Marsden Hospital, Royal Marsden NHS Foundation Trust, London, UK.
Dimitri TzanisDepartment of Surgical Oncology, Institut Curie, PSL University, Paris, France.
Jacek SkoczylasDepartment of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Samuel J FordDepartment of Surgery, University Hospitals Birmingham, Birmingham, UK.
Deanna NgDepartment of Surgical Oncology, Princess Margaret Cancer Centre/Mount Sinai Hospital, Toronto, ON, Canada.
John E MullinaxSarcoma Department, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Hayden SnowDepartment of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Rick L HaasDepartment of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Dario CallegaroDepartment of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Myles J SmithSarcoma Unit, Department of Academic Surgery, Royal Marsden Hospital, Royal Marsden NHS Foundation Trust, London, UK.
Toufik BouhadibaDepartment of Surgical Oncology, Institut Curie, PSL University, Paris, France.
Silvia StacchiottiDepartment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Robin L JonesDepartment of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK.
Thomas DeLaneyDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Christina L RolandDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chandrajit P RautDepartment of Surgery, Brigham and Women's Hospital, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Alessandro GronchiDepartment of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. alessandro.gronchi@istitutotumori.mi.it.
Transatlantic Australasian RPS Working Group (TARPSWG)
Fondazione IRCCS Istituto Nazionale dei Tumori · ITBrigham and Women's Hospital · USMoffitt Cancer Center · USMount Sinai Hospital · CANIHR Surgical Reconstruction and Microbiology Research Centre · GBPeter MacCallum Cancer Centre · AURoyal Marsden Hospital · GBRoyal Marsden NHS Foundation Trust · GBThe Maria Sklodowska-Curie National Research Institute of Oncology · PLThe Netherlands Cancer Institute · NLUniversité Paris Sciences et Lettres · FREmory University · USHarvard University · USInstitut Bergonié · FRInstitut Curie · FRLudwig-Maximilians-Universität München · DEPrincess Margaret Cancer Centre · CASamsung Medical Center · KRThe University of Texas MD Anderson Cancer Center · USUniversity of Ottawa · CA

Funding

Leveraging the Lymphocytic Infiltration of Soft Tissue Sarcoma for Autologous Cellular ImmunotherapyK08CA252642 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI MULLINAX, JOHN · 2020 to 2024
$1.2M
NCI NIH HHS K08 CA252642
6 · The paper itself

Abstract

backgroundRetroperitoneal soft tissue sarcomas comprise a heterogeneous group of rare tumors of mesenchymal origin that include several well-defined histologic subtypes. In 2015, the Transatlantic Australasian RPS Working Group (TARPSWG) published consensus recommendations for the best management of primary retroperitoneal sarcoma (RPS). Since then, through international collaboration, new evidence and knowledge have been generated, creating the need for an updated consensus document.

methodsThe primary aim of this study was to critically evaluate the current evidence and develop an up-to-date consensus document on the approach to these difficult tumors. The resulting document applies to primary RPS that is non-visceral in origin, with exclusion criteria as previously described. The relevant literature was evaluated and an international group of experts consulted to formulate consensus statements regarding the best management of primary RPS. A level of evidence and grade of recommendation were attributed to each new/updated recommendation.

resultsManagement of primary RPS was considered from diagnosis to follow-up. This rare and complex malignancy is best managed by an experienced multidisciplinary team in a specialized referral center. The best chance of cure is at the time of primary presentation, and an individualized management plan should be made based on the 29 consensus statements included in this article, which were agreed upon by all of the authors. Whenever possible, patients should be enrolled in prospective trials and studies.

conclusionsOngoing international collaboration is critical to expand upon current knowledge and further improve outcomes of patients with RPS. In addition, prospective data collection and participation in multi-institution trials are strongly encouraged.

Indexed as

Bone NeoplasmsRetroperitoneal NeoplasmsSarcomaSoft Tissue NeoplasmsAdultHumans

Identifiers

PMID33852100
PMCPMC9257997
OpenAlexW3154422727

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.